anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention is a calcitonin gene-related polypeptide (CGRP) derivative and its preparing method. CGRP has important physiologic functions of reducing blood pressure, etc, but is easy to degrade in animal bodies and has short acting time. It designs a segment of DNA sequence linked with the GST genes ofEscherichia coli particle carrier pGEX-4T-2, composing a new expression plasmid pGEX-CGRP with CGRP. It makes separation and extraction on the fusion protein produced by Escherichia coli fermentation to prepare CGRP derivative I. In addition, It clones the genes of the two decompressing small peptides: HHL and PRLKPW to CGRP genes, composing two expressing particles: pGEX-CGRP-3AA and pGEX-CGRP-6AA, transferred into the Escherichia coli cells, then fermenting and separating CGRP derivatives II and III from Escherichia coli cells. The above derivatives can be used in preparing the medicines of curing cardiovascular disease.
BACKGROUND: Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis of LC complicated by CPA has not been elucidated. This study investigated the clinical implications of concomitant CPA in patients with LC undergoing anticancer drug treatment.
METHODS: Between January 2010 and May 2020, we consecutively enrolled patients with LC complicated with CPA at five different institutions in Japan. We analyzed patients with LC complicated by CPA who received anticancer drug treatment.
RESULTS: A total of 10 patients with LC complicated by CPA received anticancer drug treatment. The median overall survival (OS) was 14.57 months (95% confidence interval [CI]: 5.37-21.67). The cause of death in all patients was LC. Six of the seven patients with LC did not show worsening pulmonary aspergillosis lesions during the anticancer drug treatment. Although two patients discontinued anticancer drug treatment due to pneumonitis, CPA complications did not interfere with the continuation of anticancer drug treatment. In univariate analyses, squamous histology (p = 0.01) and body mass index (<18.5 kg/m2) (p = 0.0008) were significantly associated with poorer OS.
CONCLUSIONS: This study demonstrated that the cause of death in LC patients with concomitant CPA who received anticancer drug treatments and effective antifungal treatment was LC progression. Further large-scale studies are needed to identify the effect of CPA in patients with LC.
<P>PROBLEM TO BE SOLVED: To provide additional HGF modulators that can be used as therapeutic and diagnostic agents.  <P>SOLUTION: The invention is based, in part, upon the discovery of a family of binding proteins that specifically bind HGF, in particular, human HGF. The binding proteins are antibody-based in so far as they contain antigen (i.e., HGF) binding sites based on the CDRs of a family of antibodies that specifically bind HGF. The family of binding proteins specifically bind, and neutralize the activity of, HGF, in particular, human HGF. As for the therapeutic activity, the binding proteins can be used as the therapeutic agents for specific HGF reactive disorders, for example, a specific HGF reactive tumor.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Andrographolide has anti-inflammatory and neuroprotective effects, making it a potential therapeutic option for Alzheimer's disease (AD). Our research group optimized its structure in a previous study to minimize the risk of renal toxicity, which would beneficial for future clinical research. This study aims to examine the impact of Andro-III on enhancing cognitive learning ability in 3xTg-AD mice, as well as the mechanisms involved. Andro-III improved spatial learning ability, prevented the loss of Nysted's vesicles, reduced the accumulation of β-amyloid (Aβ) and tau proteins, and suppressed microglial activation. Further research found that the expression of nuclear factor kappa-B RelA (NF-κB p65) expression and glycogen synthase kinase-3β (GSK-3β) activity were inhibited, while CREB was upregulated in brain tissue treated with Andro-III. Moreover, Andro-III downregulated the expression of IBA1 and inflammatory factors in microglial cells of mice induced by Aβ. The regulation of the GSK-3β/NF-κB/CREB pathway was similar to that observed in 3xTg-AD mice. Therefore, Andro-III modulates neuroinflammation and attenuates neuropathological changes of AD via the GSK-3β/NF-κB/CREB pathway.
This study investigated the impact of bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) on diaphragm configuration. We successfully analyzed the diaphragm index using a newly developed quantitative computed tomography (QCT) tool before and after EBV treatment in forty patients with severe emphysema. We evaluated whether changes in the diaphragm index were associated with improvements in forced expiratory volume in 1 s (FEV1), residual volume (RV), Saint Georges Respiratory Questionnaire (SGRQ), and 6-min walking distance (6MWD) using Spearman's rho. The EBV treatment influenced the diaphragm configuration only on the treated side, resulting in an increased diaphragm curvature. There were significant associations of relative diaphragm index changes on the treated lung side or the entire diaphragm with improvements in FEV1 and 6MWD. These findings provide valuable insights into how EBV treatment affects the diaphragm in COPD patients.
BACKGROUND: Neck and low back pain are prevalent issues among office workers due to prolonged sitting, necessitating effective interventions. Dynamic seat cushion, designed to promote postural shifts, have emerged as promising solutions to address this concern. This study aims to evaluate the effectiveness of a dynamic seat cushion on recovery and recurrence of neck and/or low back pain in office workers.
METHODS: This study used 6-month follow-up data of a randomized controlled trial, involving 66 office workers who reported neck and/or low back pain during the trial. At baseline, participants were cluster-randomized into an intervention group, which received a dynamic seat cushion designed to encourage postural shifts, or a control group, which received a placebo seat pad. Health outcomes included recovery duration and recurrence of pain. Analyses utilized log rank test and Cox proportional hazard models.
RESULTS: The recovery rate from neck and/or low back pain was 100% for the intervention group, and 86% for the control group. The median recovery duration of participants who reported pain during the 6-month period was 1 month in the intervention group and 3 months in the control group. The intervention group had a higher probability of recovery compared to the control group (HRadj 4.35, 95% CI 1.87-10.11; p < 0.01). The recurrence rate of neck and low back pain was 27% in the intervention group, which was 75% in the control group. The Hazard Ratio, after adjustment, for the intervention group compared to the control group was 0.50 (95% CI = 0.11-2.12).
CONCLUSIONS: A dynamic seat cushion that encourages postural shifts shortened recovery duration of neck and low back pain among office workers. Due to small numbers, a potentially relevant reduction in the recurrence of neck and low back pain could not be statistically confirmed. A power analysis was not conducted for this secondary analysis, and future studies should be designed with adequate sample sizes to explore the recurrence of pain with greater statistical power.
TRIAL REGISTRATION: This trial is retrospectively registered under the Thai Clinical Trials Registry: TCTR20230623002 (23/06/2023).
AIMS: The aim was to investigate the relationship between microvascular function, cardiovascular risk profile, and subclinical atherosclerotic burden.
METHODS AND RESULTS: The study enrolled 3809 individuals, 50-65 years old, participating in the population-based observational cross-sectional Swedish CArdioPulmonary bioImage Study. Microvascular function was assessed in forearm skin using an arterial occlusion and release protocol determining peak blood oxygen saturation (OxyP). Cardiovascular risk was calculated using the updated Systematic Coronary Risk Evaluation [SCORE2; 10-year risk of fatal and non-fatal cardiovascular disease (CVD) events]. The OxyP was compared with coronary artery calcification score (CACS) and to plaques in the carotid arteries. Individuals with OxyP values in the lowest quartile (Q1; impaired microvascular function) had a mean SCORE2 of 5.8% compared with 3.8% in those with the highest values of OxyP (Q4), a relative risk increase of 53%. The risk of having a SCORE2 > 10% was five times higher for those in Q1 (odds ratio: 4.96, 95% confidence interval: 2.76-8.93) vs. Q4 when adjusting for body mass index and high-sensitivity C-reactive protein. The OxyP was lower in individuals with CACS > 0 and in those with both carotid plaques and CACS > 0, compared with individuals without subclinical atherosclerotic burdens (87.5 ± 5.6% and 86.9 ± 6.0%, vs. 88.6 ± 5.8%, P < 0.01).
CONCLUSION: In a population without CVD or diabetes mellitus, impaired microvascular function is associated with cardiovascular risk profiles such as higher SCORE2 risk and CACS. We suggest that OxyP may serve as a microcirculatory functional marker of subclinical atherosclerosis and CVD risk that is not detected by structural assessments.
Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role has not been elucidated. We describe here a role for Siglec-6 in migration and adhesion of CLL B cells to CLL- bone marrow stromal cells (BMSCs) in vitro and compromised migration to bone marrow and spleen in vivo. Mass spectrometry analysis revealed interaction of Siglec-6 with DOCK8, a guanine nucleotide exchange factor. Stimulation of MEC1-002 CLL cells with a Siglec-6 ligand, sTn, results in Cdc42 activation, WASP protein recruitment and F-actin polymerization, which are all associated with cell migration. Therapeutically, a Siglec-6/CD3-bispecific T-cell-recruiting antibody (T-biAb) improves overall survival in an immunocompetent mouse model and eliminates CLL cells in a patient derived xenograft model. Our findings thus reveal a migratory role for Siglec-6 in CLL, which can be therapeutically targeted using a Siglec-6 specific T-biAb.
Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
The present invention relates to woodlouse which is used for treating hyperostosis, bony spur, etc. and has a predominant effect. Woodlouse accounts for 10% to 30% of medicines of compatibility, other medicines of compatibility can comprise 50 to 100 parts of curare, 50 to 100 parts of raw Rhizoma Arisaematis, 50 to 100 parts of raw pinellia tuber, 50 to 100 parts of raw common monkshood mother root, 50 to 100 parts of raw kusnezoff monkshood root, 50 to 100 parts of fructus mume and 50 to 100 parts of hawthorn fruit, and many kinds of traditional Chinese medicines of frankincense, myrrh, rhizoma corydalis, hemlock parsley, eupolyphaga, common clubmoss herb, tuberculate speranskia herb, white peony alba, radix glycyrrhiza, camphor, etc. can be added. Compound Yantongning paste prepared by the medicines has a good inflammation relieving and analgesic effect, can relieve and eliminate partial aseptic inflammation, improve partial microcirculation, improve the ischemia anaerobic condition of the tissue, lower the internal pressure of the bones and joints and restore the stress balancing of the bones and joints, and the dynamic balance of microcirculation, so that symptoms of pain, swelling, ankylosis, limitation of motion, etc. caused by hyperostosis. The present invention is an ideal external application medicine for treating hyperostosis.
Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
BACKGROUND: Syncope is a common condition that increases the risk of injury and reduces the quality of life. Abdominal pain as a precursor to vasovagal syncope (VVS) in adults is rarely reported and is often misdiagnosed.​.
METHODS: We present three adult patients with VVS and presyncopal abdominal pain diagnosed by synchronous multimodal detection (transcranial Doppler [TCD] with head-up tilt [HUT]) and discuss the relevant literature.
RESULTS: Case 1: A 52-year-old man presented with recurrent decreased consciousness preceded by six months of abdominal pain. Physical examinations were unremarkable. Dynamic electrocardiography, echocardiography, head and neck computed tomography angiography, magnetic resonance imaging (MRI), and video electroencephalogram showed no abnormalities. Case 2: A 57-year-old woman presented with recurrent syncope for 30 + years, accompanied by abdominal pain. Physical examination, electroencephalography, and MRI showed no abnormalities. Echocardiography showed large right-to-left shunts. Case 3: A 30-year-old woman presented with recurrent syncope for 10 + years, with abdominal pain as a precursor. Physical examination, laboratory analysis, head computed tomography, electrocardiography, and echocardiography showed no abnormalities. Syncope secondary to abdominal pain was reproduced during HUT. Further, HUT revealed vasovagal syncope, and synchronous TCD showed decreased cerebral blood flow; the final diagnosis was VVS in all cases.
CONCLUSIONS: Abdominal pain may be a precursor of VVS in adults, and our findings enrich the clinical phenotypic spectrum of VVS. Prompt recognition of syncopal precursors is important to prevent incidents and assist in treatment decision-making. Abdominal pain in VVS may be a sign of sympathetic overdrive. Synchronous multimodal detection can help in diagnosing VVS and understanding hemodynamic mechanisms.
The invention relates to a preparation method and a quality control method of an antiviral external preparation. The preparation comprises the following medicinal materials: the honeysuckle, asarum, wild chrysanthemum, houttuynia cordata, sweet wormwood, radix isatidis and borneol have good application prospect as an antiviral external preparation. The preparation method comprises pulverizing the above materials except Borneolum Syntheticum into coarse powder, soaking, extracting, concentrating the extractive solution to a certain proportion, adding Borneolum Syntheticum solution, precipitating with ethanol overnight, removing impurities, and filtering. Concentrating the filtrate, adding appropriate amount of adjuvants, and fixing volume to obtain preparation. The preparation method is simple to operate and easy for industrial production. The invention also constructs an HPLC characteristic spectrum as a quality control method, wherein the chlorogenic acid characteristic peak is an S peak, the retention time of the characteristic peak is uniformly distributed, the peak symmetry is good, the base line is stable, and the separation degree meets the requirement. The quality control method can effectively realize comprehensive control of the quality of the preparation, and is convenient, quick, accurate, reliable and good in reproducibility.
After being consented, the participant will be provided with ChatGPT-4 application and a brief orientation to the program. The participant will then be instructed to ask ChatGPT about the participant's primary presenting problem with will be discussed at their urogynecology consultation. The participant will be allowed up to five follow-up/clarification entries into the Chat GPT program, but may finish asking questions at any time. This should take no more than five minutes of the participant's time. After completing this, the participant will be returned to the waiting room, and will proceed through the urogynecology visit as normal.
Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE: A composition containing Solanum muricatum Ait. and silkpeptide for relieving hangover and improving liver function is provided. CONSTITUTION: A composition for preventing and treating liver damage contains Solanum muricatum Ait. Hydrolysate which is hydrolysed by pectinase, arabinase, or glucoamylase; and silk peptide in a weight ratio of 10:90-40:60 as an active ingredient. The composition is a food composition. A method for manufacturing the composition comprises: a step of hydrolyzing Solanum muricatum Ait. With pectinase, arabinase, or glucoamylase; and a step of adding the silk peptide to Solanum muricatum Ait. Hydrolysate.
The risks of bone loss and osteoporosis increase significantly after menopause. Although hormone therapy (HT) can spare menopausal women from bone loss and other menopausal symptoms, Women's Health Initiative (WHI) findings indicate significant potential health risks associated with HT. This has prompted women to switch from HT to naturally occurring compounds similar to estrogen, such as those derived from soy, in the hope that estrogens from plant sources can provide benefits while sparing adverse effects caused by prescribed estrogens. However, the long-term efficacy and safety of plant estrogens are unknown. This study will evaluate the effectiveness of treatment using purified soy isoflavones, a dietary source of phytoestrogens, in preventing bone loss, menopausal symptoms, and other changes associated with estrogen deficiency in young menopausal women. The "Soy Phytoestrogens As Replacement Estrogen (SPARE)" study will provide a foundation of knowledge from which menopausal women and their doctors can begin to make more informed decisions regarding HT and other treatment options.

Enrollment into the study will occur over 3 years, with each participant taking part in the study for a total of 2 years. Participants will be randomly assigned to one of two groups; the first group will receive a 200 mg dose of soy isoflavones daily and the second group will receive placebo daily. There will be 10 study visits: screening, study entry, randomization at Month 1, six follow-up visits at Months 2, 4, 8, 12, 16, 20, and a final visit at the end of active participation at Month 24. At each study visit, participants will have blood drawn, provide urine samples, answer questionnaires, and have mammograms and bone density tests.
The present invention provides an oral administration traditional Chinese medicine for treating singultus after cerebral hemorrhage. The medicine is characterized in that the medicine raw materials with active ingredient are: 6-18 parts by weight of raw rheubarb, 6-18 parts by weight of peach seed, 3-16 parts by weight of cassia twig, 3-16 parts by weight of liquorice, 1-6 parts by weight of mirabilite, 3-16 by weight of flos caryophyllata, 6-18 parts by weight of shidi, 3-16 by weight of bitter orange. All raw materials are mixed into earthen pot except raw rheubarb and mirabilite, then steep fully with moderate water; putting raw rheubarb after boiling by quick fire, then boiling medicine with half hour, filtering out medicine liquid; boiling the remainder added moderate water with half hour by slow fire, filtering out medicine liquid. Two parts medicine liquid are mixed and cooled thoroughly. Conscious patient drinks the mdeicine liquid three times a day, coma patient is injected via gastric canal two times a day. The mirabilite is divided into two equal parts and is taken with water when drinking medicine liquid, and can be injected into coma patient via gastric canal after mixed with medicine liquid. The traditional Chinese medicine is used for quick and efficient treating singultus after cerebral hemorrhage with 87% cure rate and 100% effective rate.
Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
The present invention a special medicine for curing chronic nephritis, called a nephritis healing pill. According to a Chinese medicine theory, the cause and the pathological mechanism of chronic nephritis, a therapeutic method is drafted. The present invention adopts astragalus root, pilose asiabell root, tuckahoe, water plantain, semen pharbitidis, lepidium seed, rhubarb, motherwort, tuckahoe, forsythia fruit, cicada slough, aconite root, achyranthes root, Chinese yam, red sage root, leeches, ginger and Chinese date which are ground into fine power, filtered by a 100-mesh screen and refined into pills with honey. The weight of each pill is 9 grams. Each pill is for each time and twice to thrice each day. The present invention is taken by cold boiled water and is mainly used for curing chronic nephritis and preventing and curing chronic kidney competence failure.
Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
OBJECTIVES: To compare artificial intelligence (AI)-driven web-based platform and manual measurements for analysing facial asymmetry in craniofacial CT examinations.
METHODS: The study included 95 craniofacial CT scans from patients aged 18-30 years. The degree of asymmetry was measured based on AI platform-predefined anatomical landmarks: sella (S), condylion (Co), anterior nasal spine (ANS), and menton (Me). The concordance between the results of automatic asymmetry reports and manual linear 3D measurements was calculated. The asymmetry rate (AR) indicator was determined for both automatic and manual measurements, and the concordance between them was calculated. The repeatability of manual measurements in 20 randomly selected subjects was assessed. The concordance of measurements of quantitative variables was assessed with interclass correlation coefficient (ICC) according to the Shrout and Fleiss classification.
RESULTS: Erroneous AI tracings were found in 16.8% of cases, reducing the analysed cases to 79. The agreement between automatic and manual asymmetry measurements was very low (ICC < 0.3). A lack of agreement between AI and manual AR analysis (ICC type 3 = 0) was found. The repeatability of manual measurements and AR calculations showed excellent correlation (ICC type 2 > 0.947).
CONCLUSIONS: The results indicate that the rate of tracing errors and lack of agreement with manual AR analysis make it impossible to use the tested AI platform to assess the degree of facial asymmetry.